Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sanofi ( (SNY) ) has provided an announcement.
On February 13, 2025, Sanofi announced the discontinuation of the E.mbrace phase 3 study for its extraintestinal pathogenic E. coli vaccine, following an independent analysis that found the vaccine lacked sufficient efficacy. Despite no safety issues and the rigorous nature of the study conducted worldwide, the decision impacts financials with a $250 million impairment charge, slightly lowering the 2024 EPS. Sanofi remains committed to pioneering advancements in high-need areas.
More about Sanofi
Sanofi is a global healthcare company focused on innovative solutions to improve people’s lives. They provide life-changing treatments and vaccines, emphasizing sustainability and social responsibility. Sanofi is listed on EURONEXT and NASDAQ.
YTD Price Performance: 13.22%
Average Trading Volume: 2,541,532
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $136.4B
Find detailed analytics on SNY stock on TipRanks’ Stock Analysis page.